US OptionsDetailed Quotes
SGMT250516C5000
- 0.10
- +0.05+100.00%
15min DelayTrading Apr 28 09:38 ET
0.10High0.03Low
0.05Open0.05Pre Close259 Volume279 Open Interest5.00Strike Price2.22KTurnover168.28%IV57.89%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1770Delta0.2110Gamma32.30Leverage Ratio-0.0089Theta0.0002Rho5.72Eff Leverage0.0019Vega
Sagimet Biosciences Stock Discussion
Sagimet Biosciences Announces Clearance of Ind for Fasn Inhibitor Tvb-3567, to Be Developed for the Treatment of Acne
“SAN MATEO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation on denifanstat's effect on triglycerides and LDL-cholesterol in advanced fibrosis patients will be delivered at the MASH Pathogenesis and Therapeutic Approac...
📊⚡️📊
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences presented Phase 2b data for denifanstat, its fatty acid synthase (FASN) inhibitor, at AASLD 2024. The FASCINATE-2 trial showed significant improvement in liver fibrosis in high-risk MASH patients, particularly in the F3 population where 49% of denifanstat-treated patients showed improvement versus 13% for placebo. AI-ba...
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Ascletis Pharma has completed enrollment of 480 patients in its Phase III clinical trial of ASC40 (denifanstat), a once-daily oral tablet for treating moderate to severe acne. The randomized, double-blind, placebo-controlled trial began on January 24, 2024, with patients divided equally between treatment and placebo groups. The study will evalua...
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced the publication of results from their Phase 2b FASCINATE-2 clinical trial of denifanstat in The Lancet Gastroenterology & Hepatology. The trial, conducted on patients with biopsy-confirmed metabolic-dysfunction associated steatohep...
No comment yet